에 대한 최신 뉴스 Birkenstock Holding (NYSE:BIRK) 주식

Birkenstock Holding

Birkenstock Holding PLC is a company that manufactures and sells footbed-based products, including sandals, closed-toe silhouettes, and other products, such as skincare and accessories, for everyday, leisure, and work. The company operates in four operating segments based on its regional hubs: Americas, Europe and APMA (Asia Pacific, Middle East and Africa). The company sells its products through two main channels: business-to-business (B2B) and direct-to-consumer (DTC).

Large Cap

News

Movers

APTV

BGNE

BIRK

MRNA

POOL

이들 10개 대형주는 지난 주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 월그린스 부츠 얼라이언스(NASDAQ:WBA)의 주가는 회사가 혼합된 3분기 실적을 보고하고 2024년 지침을 컨센서스 추정치보다 낮게 낮춘 후 24.12% 하락했다. 분석가들은 주식에 대한 가격 예측을 하향 조정했다.

모더나와 월그린스는 지난주 최악의 성과를 보인 10대 대형주 중 일부 (6월 23일-6월 29일)

General

BURL

CAVA

New Oriental Education & Technology Group

ONON

지난주 이들 10개의 대형주는 최고의 성과를 거두었다. 이들 주식이 당신의 포트폴리오에 있나요? 버켄스탁 홀딩(NYSE:BIRK)의 주가는 회사가 강력한 2분기 실적을 발표하고 연간 매출 성장 가이던스를 상향 조정한 후 22.20% 상승했다. 몇몇 애널리스트들은 목표 주가를 상향 조정했다. 

니오와 베스트 바이는 지난주 최고의 성과를 보인 10개의 대형주 중 일부

Birkenstock Holding PLC

Birks Group Inc

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

BJDX

SMST

LIFW

SMCX

LIFWW

Numinus Wellness Inc. (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/NUMIF#OTCQX">NUMIF</a>), a leader in <a href="https://www.benzinga.com/topic/psychedelic-assisted-therapies">psychedelic-assisted mental health care</a>, has <a href="https://www.investors.numinus.com/news/news-details/2024/Numinus-Wellness-Announces-Sale-of-Clinics-and-Unique-Data-Partnership-to-Increase-Access-to-Mental-Health-Care/default.aspx">announced</a> a definitive agreement with Stella, an interventional psychiatry practice, to sell its five wellness clinics in Utah for a total of $3.53 million. The transaction, expected to close by November 30, marks a strategic shift for Numinus, as it pivots towards <a href="https://www.benzinga.com/markets/cannabis/24/09/40845569/mdma-therapy-for-ptsd-faces-fda-delay-are-there-other-ways-forward">developing technology-driven solutions</a> aimed at enhancing the efficiency of mental health care providers.
<h3 class="wp-block-heading">Tech Partnership To Redefine Mental Health Clinics</h3>
In addition to the sale, Numinus and Stella will collaborate on a data-sharing initiative to launch an innovative clinic management platform. By leveraging operational insights from Stella's 12 clinics, Numinus plans to develop a software solution designed to streamline clinic operations, enhance patient outcomes and support insurance reimbursement processes.
"This transaction marks an exciting new chapter in Numinus' strategy to reshape behavioral health care," said Payton Nyquvest, founder and CEO of Numinus. "Leveraging our expertise in patient care, we're now accelerating our mission by focusing on cutting-edge technology solutions. Through our partnership with Stella, we gain unprecedented access to operational data that will enable us to develop a SaaS (software as a service) solution to redefine how clinics operate."
<h3 class="wp-block-heading">Stella Takes Over Utah Operations</h3>
Stella, known for its focus on treating PTSD, anxiety and depression through biological modalities, will assume control of Numinus' Utah clinics. The acquisition includes an upfront payment of $2.08 million, followed by $750,000 in installments throughout 2025, and up to $700,000 in deferred compensation.
"Stella's expansion into Utah brings additional life-changing treatments to the community while supporting Numinus' broader tech initiatives," stated Michael Gershenzon, co-founder and CEO of Stella. "This partnership reflects our commitment to improving behavioral health systems and processes, ultimately enhancing patient care."
<h3 class="wp-block-heading">An Asset-Light Business Model With Enhanced Focus</h3>
With the sale of its clinics, Numinus will shift towards an asset-light model, focusing on its business units like Cedar Clinical Research and the Numinus Network. The strategy aims to integrate clinical research, practitioner training and technology solutions, supporting mental health providers worldwide. The move is part of a broader effort to ease the operational burdens faced by healthcare professionals, particularly as demand for treatments like <a href="https://www.benzinga.com/topic/ketamine-therapy">ketamine</a> and Spravato continues to rise.
"Stella will bolster our clinical solutions offering, leveraging their deep expertise in patient care," Nyquvest added. "We expect strong demand for our Numinus Network Solutions as mental health practitioners navigate growing requests for care."
Cover image made with AI

Cannabis

Psychedelics

NUMIF

Numinus Wellness Sells US Clinics, Partners With Stella For Tech-Driven Mental Health Solutions

President-elect Donald Trump has chosen former Representative Doug Collins (R-GA) to lead the <a href="https://www.benzinga.com/cannabis">U.S. Department of Veterans Affairs (VA). </a>
The decision has sparked discussions about how the agency might handle medical cannabis issues, given his inconsistent track record on the issue, as <a href="https://www.marijuanamoment.net/trumps-pick-to-lead-va-voted-against-letting-agency-doctors-recommend-medical-marijuana-to-veterans-before-he-adopted-a-pro-reform-position/">reported</a> Marijuana Moment.
<h3 class="wp-block-heading">Collins' Record On Cannabis</h3>
During his time in Congress, Collins opposed efforts to expand access to medical cannabis for veterans. Between 2014 and 2016, he voted against three proposals that would have allowed VA doctors to recommend cannabis to their patients.
See Also: <a href="https://www.benzinga.com/markets/cannabis/24/11/42018478/trumps-cabinet-choices-will-his-administration-support-or-restrict-cannabis">Trump&#8217;s Cabinet Choices: Will His Administration Support Or Restrict Cannabis?</a>
Collins' views began to shift in 2019. He supported the STATES Act, which would protect state marijuana programs from federal interference, and co-signed a letter with Rep. Matt Gaetz (R-FL), urging Congress to take action on cannabis policy. 
"We believe this Committee and this Congress must act to clarify the rights and responsibilities, relative to cannabis, of individuals, physicians, businesses, medical patients, and law enforcement officials," they wrote.
Later that year, Collins backed a bipartisan bill to protect banks that serve marijuana businesses in states where it is legal. However, he did not take part in a 2020 vote on federal cannabis legalization.
<h3 class="wp-block-heading">Collins' Stance On Psychedelics</h3>
When it comes to psychedelics, there isn't much known about Collins's stance. However, his shifting views on cannabis policy hint that he could be open to exploring different approaches.
<h3 class="wp-block-heading">Cannabis At The VA</h3>
VA policy has long prohibited its doctors from recommending cannabis, citing marijuana's classification as a Schedule I controlled substance under federal law. This stance has remained consistent across both Republican and Democratic administrations, despite growing support for change in Congress.
Recent efforts to address this issue include a Senate Appropriations Committee request for the VA to explore cannabis as an alternative to opioids. Lawmakers have also introduced measures that would allow VA doctors to recommend cannabis in states where it is legal. These efforts have gained bipartisan support, but none have yet become law.
Veterans service organizations have pushed for further reforms, including expanded research into the potential benefits of cannabis. Last year, a Senate committee approved a bill to study cannabis for veterans with certain medical conditions, but it failed to advance to a floor vote.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/health-care/24/11/42017583/trumps-go-wild-on-health-plan-puts-rfk-jr-in-charge-what-it-means-for-cannabis-and-psychedelics-reform">Trump&#8217;s &#8216;Go Wild On Health&#8217; Plan Puts RFK Jr. In Charge: What It Means For Cannabis And Psychedelics Reform</a></li>
</ul>
Cover image made with AI.

Government

Politics

Markets

Trump-Appointed Doug Collins To Lead VA: What's Next For Cannabis and Psychedelics In Veterans' Healthcare?

Chardan Capital analyst Daniil Gataulin maintains Clearside Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSD#NASDAQ">CLSD</a>) with a Buy and maintains $6 price target.

Price Target

Analyst Ratings

CLSD

Chardan Capital Maintains Buy on Clearside Biomedical, Maintains $6 Price Target

Chardan Capital analyst Daniil Gataulin maintains Cognition Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGTX#NASDAQ">CGTX</a>) with a Buy and maintains $11 price target.

CGTX

Chardan Capital Maintains Buy on Cognition Therapeutics, Maintains $11 Price Target

Telsey Advisory Group analyst Cristina Fernandez maintains Williams-Sonoma (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSM#NYSE">WSM</a>) with a Outperform and maintains $165 price target.

Telsey Advisory Group Maintains Outperform on Williams-Sonoma, Maintains $165 Price Target

– Approval based on positive data from the AUGMENT-101 clinical trial, in which Revuforj delivered robust and durable rates of remission in R/R acute leukemia patients with a KMT2A translocation –
– Syndax to host conference call today at 6:00 p.m. ET –
WALTHAM, Mass., Nov. 15, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDX#NASDAQ">SNDX</a>) today announced that the U.S. Food and Drug Administration (FDA) has approved Revuforj&#xAE; (revumenib) as the first and only menin inhibitor for the treatment of relapsed or refractory (R/R) acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients one year and older. The FDA previously granted Breakthrough Therapy and Fast Track designations as well as Priority Review for Revuforj. The New Drug Application (NDA) received approval through the FDA's Real Time Oncology Review (RTOR) program.

Biotech

SNDX

Syndax Announces FDA Approval Of Revuforj, The First And Only Menin Inhibitor To Treat Adult And Pediatric Patients With Relapsed Or Refractory Acute Leukemia With A KMT2A Translocation

IT Tech Packaging (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ITP#AMEX">ITP</a>) reported quarterly losses of $(0.20) per share. This is unchanged from the same period last year. The company reported $25.08 million in sales this quarter. This is a 59.03 percent increase over sales of $15.77 million the same period last year.

Earnings

IT Tech Packaging Q3 EPS $(0.20), Same YoY, Sales $25.08M Up From $15.77M YoY

RumbleOn, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMBL#NASDAQ">RMBL</a>) (the "Company" or "RumbleOn") announced today that the close of business (4:00 p.m. Central Time) on November 25, 2024 has been fixed as the record date (the "Record Date") for its previously announced proposed $10.0 million registered equity rights offering (the "Rights Offering"), which was announced in a Form 8-K filed with the U.S. Securities and Exchange Commission ("SEC") on November 12, 2024.

Offerings

RMBL

RumbleOn Announces That The Close Of Business On November 25, 2024 Has Been Fixed As The Record Date For Its Previously Announced Proposed $10M Registered Equity Rights Offering

Telsey Advisory Group analyst Dana Telsey maintains European Wax Center (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWCZ#NASDAQ">EWCZ</a>) with a Outperform and maintains $8 price target.

EWCZ

Telsey Advisory Group Maintains Outperform on European Wax Center, Maintains $8 Price Target

<a href="https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20241115-1475367/1475367_4rcm.pdf" title="https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20241115-1475367/1475367_4rcm.pdf">https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20241115-1475367/1475367_4rcm.pdf</a>

FOUR

Shift4 Payments Will Replace R1 RCM In The S&P Midcap 400 Effective Prior To The Opening Of Trading On Wednesday, November 20

China Green Agriculture, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CGA#NYSE">CGA</a>) has changed its name to Enlightify Inc., effective November 25, 2024. Its ticker symbol will change to ENFY effective November 25, 2024, and it is expected to begin trading under that symbol on November 26, 2024. The Company mainly produces and distributes humic acid-based compound fertilizers, other varieties of compound fertilizers and agricultural products through its subsidiaries in China.

China Green Agriculture Changes Name to Enlightify Inc.; Its Ticker Symbol Will Change To 'ENFY' Effective November 25, 2024, And It Is Expected To Begin Trading Under That Symbol On November 26, 2024

Alpha Cognition (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACOG#NASDAQ">ACOG</a>) reported quarterly losses of $(0.31) per share. This is a 63.1 percent increase over losses of $(0.84) per share from the same period last year.

ACOG

Alpha Cognition Q2 EPS $(0.31) Up From $(0.84) YoY

D. Boral Capital analyst Jason Kolbert maintains NRX Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRXP#NASDAQ">NRXP</a>) with a Buy and maintains $31 price target.

NRXP

D. Boral Capital Maintains Buy on NRX Pharmaceuticals, Maintains $31 Price Target

D. Boral Capital analyst Jason Kolbert maintains VolitionRX (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VNRX#AMEX">VNRX</a>) with a Buy and maintains $5 price target.

VNRX

D. Boral Capital Maintains Buy on VolitionRX, Maintains $5 Price Target

Best And Worst Performers Since August 5, 2024

Catalyst Watch: Spotlight on Micron, Southwest Airlines, and FOMC speakers

Wall Street Breakfast: The Week Ahead

In a report released today, Matthew Boss from J.P. Morgan maintained a Buy rating on Birkenstock Holding plc (BIRK – Research Report), with a price...

Birkenstock Holding plc: Strong Buy Rating on Robust Sales and Growth Trajectory

Telsey Advisory analyst Dana Telsey maintained a Buy rating on Birkenstock Holding plc (BIRK – Research Report) today and set a price target of $70...

Telsey Advisory Sticks to Their Buy Rating for Birkenstock Holding plc (BIRK)

Just Do It! Brand Name Lessons From Nike's Troubles

Birkenstock Holding plc (BIRK) has received a new Buy rating, initiated by BTIG analyst, Janine Stichter. Janine Stichter's rating is based on a mu...

Birkenstock Holding plc: A Strong Buy on Robust and Predictable Growth with Undervalued Market Position

Baron Focused Growth Fund Q3 2024 Shareholder Letter

Telsey named the following stocks as the best positioned for the holidays in each sector: adidas (ADDYY) and Dick's Sporting Goods (DKS) best posit...

Telsey names its Holiday 2024 Top Picks

Birkenstock Holding plc (BIRK) has released an update. Birkenstock Holding plc is set to release its fourth quarter and full fiscal year 2024 finan...

Birkenstock Holding to Announce Fiscal Year Results

AAPL

ABNB

ACGL

ADDYY

AERG

AFRM

ALLY

ALXO

AMZN

AZUL

BBWI

BCAP

BMRN

BROE

BRZE

CELH

COST

CROX

CSGP

DECK

DJTWW

DLTR

DNUT

DUOL

EBAY

ETON

FIGS

FIVE

GOOG

GRDN

GWRE

HUBS

IART

IBKR

IDXX

ILMN

IMRX

INTU

LGCY

LUNR

MPAA

MSCI

NBIX

NXST

PGHL

PLTR

PYPL

SFIX

SHOP

SIRI

SPOT

TSCO

TSLA

TURB

UNLYF

VERV

VSTO

WOLF

ZETA

Press Releases

Refinancing of Credit Facilities and Voluntary Early Repayments of Around USD 50 Million Optimize Financing Conditions and Further Drive Balance Sheet Deleveraging

Birkenstock Reports Record Second Quarter Revenue, up 23% Y/Y, Driven by Strong Consumer Demand Across All Segments, Channels and Categories; Company Raises Full-Year Revenue Growth Guidance to 20%

Events

Birkenstock Announces June Conference Participation

Birkenstock Announces Launch of Secondary Offering

Birkenstock Announced Pricing of $756 Million Secondary Offering of Ordinary Shares

Birkenstock Announces Third Quarter 2024 (Ended June 30, 2024) Results Date and Conference Call

Birkenstock Reports Record Third Quarter Revenue, up 19% Year-Over-Year, Driven by Continued Strong and Growing Consumer Demand

Birkenstock Announces September Conference Participation

Birkenstock Announces Fourth Quarter and Full Fiscal Year 2024 (Ended September 30, 2024) Results Date and Conference Call

Allbirds

Crocs

Deckers Outdoor

Nike

Rocky Brands

Steven Madden

Skechers USA

Wolverine World Wide

BTIG

Telsey Advisory Group

BMO Capital

Evercore ISI Group

Stifel

이들 10개 대형주는 지난주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
<ol>
<li>월그린스 부츠 얼라이언스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>)의 주가는 회사가 혼합된 3분기 실적을 보고하고 2024년 지침을 <a href="https://www.benzinga.com//node/39523397" target="_blank" rel="noreferrer noopener">컨센서스 추정치</a>보다 낮게 낮춘 후 24.12% 하락했다. 분석가들은 주식에 대한 <a href="https://www.benzinga.com/quote/wba/analyst-ratings" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">가격 예측</a>을 하향 조정했다.</li>
<li>플로어 앤 데코 홀딩스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FND#NYSE">FND</a>)의 주식은 예상보다 나쁜 5월 주택판매 경제 데이터에 대한 반응으로 13.41% 급락했다.</li>
<li>모더나(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>)의 주가는 회사의 RSV 백신이 <a href="https://www.benzinga.com//node/39508239" target="_blank" rel="noreferrer noopener">50%의 효능을 보인</a> 이후 11.76% 급락했다.</li>
<li>버켄스탁 홀딩(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIRK#NYSE">BIRK</a>)의 주식은 회사가 매각 주주가 최대 1,400만 주 보통주를 <a href="https://www.benzinga.com//node/39467369" target="_blank" rel="noreferrer noopener">공모</a>한다고 발표한 후 주가는 10.86% 하락했다.</li>
<li>베이진(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BGNE#NASDAQ">BGNE</a>)의 주식은 지난주에 9.70% 하락했다.</li>
<li>풀 코퍼레이션(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POOL#NASDAQ">POOL</a>)의 주식은 회사가 <a href="https://www.benzinga.com//node/39484866" target="_blank" rel="noreferrer noopener">FY24 EPS 가이던스를 낮춘 </a>이후 9.19% 떨어졌다.</li>
<li>징동닷컴(JD닷컴)(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>)의 주식은 미국이 <a href="https://www.benzinga.com//node/39521291" target="_blank" rel="noreferrer noopener">중국 기술에 대한 투자</a>를 억제하는 규정을 발표한 이후 8.89% 하락했다.</li>
<li>에코페트롤(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EC#NYSE">EC</a>)의 주식은 8.02% 급락했다</li>
<li>인터내셔널 페이퍼(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IP#NYSE">IP</a>)의 주식은 수자노(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUZ#NYSE">SUZ</a>)가 <a href="https://www.benzinga.com//node/39519611" target="_blank" rel="noreferrer noopener">인수 거래를 중단</a>하기로 한 이후 7.98% 하락했다.</li>
<li>마이크론 테크놀로지(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>)의 주식은 지난 주 <a href="https://www.benzinga.com//node/39520174" target="_blank" rel="noreferrer noopener">3분기 실적과 4분기 전망</a>에 대한 정보가 나온 이후 7.62% 하락했다.</li>
</ol>
다음 기사 읽기:
<ul>
<li><a href="https://kr.benzinga.com/news/%eb%a6%ac%eb%b9%84%ec%95%88%ea%b3%bc-%ec%b9%b4%eb%b0%94%eb%82%98%eb%8a%94-%ec%a7%80%eb%82%9c%ec%a3%bc-%ec%b5%9c%ea%b3%a0%ec%9d%98-%ec%84%b1%ea%b3%bc%eb%a5%bc-%eb%b3%b4%ec%9d%b8-10%eb%8c%80-%eb%8c%80/" target="_blank" rel="noopener">리비안과 카바나는 지난주 최고의 성과를 보인 10대 대형주 중 일부 (6월 23일-6월 29일)</a></li>
</ul>
촬영: Shutterstock의 Lutsenko_Oleksandr

지난주 이들 10개의 대형주는 최고의 성과를 거두었다. 이들 주식이 당신의 포트폴리오에 있나요?
<ol>
<li>버켄스탁 홀딩(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIRK#NYSE">BIRK</a>)의 주가는 회사가 강력한 <a href="https://www.benzinga.com//node/39086620" target="_blank" rel="noreferrer noopener">2분기 실적을 발표</a>하고 연간 매출 성장 가이던스를 상향 조정한 후 22.20% 상승했다. 몇몇 애널리스트들은 <a href="https://www.benzinga.com/quote/birk/analyst-ratings" target="_blank" rel="noreferrer noopener">목표 주가</a>를 상향 조정했다.</li>
<li>벌링턴 스토어(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BURL#NYSE">BURL</a>)의 주식은 예상보다 나은 <a href="https://www.benzinga.com//node/39087376" target="_blank" rel="noreferrer noopener">1분기 실적</a>에 따라 21.47% 상승했다. 몇몇 분석가들은 <a href="https://www.benzinga.com/quote/burl/analyst-ratings" target="_blank" rel="noreferrer noopener">목표 가격</a>을 상향 조정했습니다.</li>
<li>딕스 스포팅 굿즈(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DKS#NYSE">DKS</a>)의 주식은 회사가 1분기 실적을 <a href="https://www.benzinga.com//node/39061439" target="_blank" rel="noreferrer noopener">발표하고</a> 2024년 가이던스를 상향 조정한 후 21.34% 상승했다. 애널리스트들은 해당 주식의 <a href="https://www.benzinga.com//node/39071891" target="_blank" rel="noreferrer noopener">목표 주가</a>를 상향 조정했다.</li>
<li>베스트 바이(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBY#NYSE">BBY</a>)의 주식은 2024년 1분기 <a href="https://www.benzinga.com//node/39084657" target="_blank" rel="noreferrer noopener">실적 발표 이후</a> 20.35% 상승했다. 주식의 목표 가격을 수정한 분석가는 거의 없다.</li>
<li>카바 그룹(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAVA#NYSE">CAVA</a>)의 주식은 1분기 실적이 상회하고 2024회계연도 <a href="https://www.benzinga.com//node/39046904" target="_blank" rel="noreferrer noopener">가이던스</a>가 상향된 후 14.51% 상승했다. 몇몇 분석가들은 예측을 <a href="https://www.benzinga.com//node/39061653" target="_blank" rel="noreferrer noopener">상향</a> 조정했다.</li>
<li>니오(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>)의 주가는 12.06% 상승했다. 니오가 중국 전기 자동차 시장에서 입지를 계속 강화함에 따라 현재 이 회사의 <a href="https://www.benzinga.com//node/39094497" target="_blank" rel="noreferrer noopener">충전 네트워크</a>에는 상하이 자동차(SAIC Motor)의 EV 유닛 IM 모터스가 포함된 것으로 알려졌다.</li>
<li>HP(휴렛 팩커드)(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPQ#NYSE">HPQ</a>)의 주식은 <a href="https://www.benzinga.com//node/39081876" target="_blank" rel="noreferrer noopener">2분기</a> 실적 발표 이후 11.62% 급등했다. 많은 분석가들은 주식에 대한 <a href="https://www.benzinga.com/quote/hpq/analyst-ratings" target="_blank" rel="noreferrer noopener">목표 가격</a>을 높였다.</li>
<li>마라톤 오일(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRO#NYSE">MRO</a>)의 주식은 코노코필립스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COP#NYSE">COP</a>)가 이 회사를 <a href="https://www.benzinga.com//node/39095128" target="_blank" rel="noreferrer noopener">인수</a>하겠다고 발표한 후 주가는 11.51% 상승했다. 11.51% 상승했다.</li>
<li>랄프 로렌(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RL#NYSE">RL</a>) 주식은 9.77% 상승했다.</li>
<li>온 홀딩 AG(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONON#NYSE">ONON</a>)의 주식은 트루이스트 증권(Truist Securities)의 분석가가 주식을 보류에서 매수로 <a href="https://www.benzinga.com//node/39042432" target="_blank" rel="noreferrer noopener">업그레이드</a>하고 목표 주가를 34달러에서 46달러로 높인 후 지난주 9.16% 상승했다.</li>
</ol>
다음 글도 읽어보기: <a href="https://kr.benzinga.com/news/%ec%84%b8%ec%9d%bc%ec%a6%88%ed%8f%ac%ec%8a%a4%ec%99%80-%ec%85%80%ec%8b%9c%ec%9a%b0%ec%8a%a4%eb%8a%94-%ec%a7%80%eb%82%9c%ec%a3%bc-%ec%b5%9c%ec%95%85%ec%9d%98-%ec%84%b1%ea%b3%bc%eb%a5%bc-%eb%b3%b4/" target="_blank" rel="noopener">세일즈포스와 셀시우스는 지난주 최악의 성과를 보인 10개의 대형주 중 일부</a>
썸네일 사진=Shutterstock

Comments

Birkenstock Holding

뉴스

에 대한 최신 뉴스 Birkenstock Holding (NYSE:BIRK) 주식

일요일, 6월 30, 2024

일요일, 6월 02, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌